Stemline Therapeutics (STML) Tops Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Stemline Therapeutics (STML) Tops Q1 EPS by 8c

Roth Affirms Stemline Therapeutics (STML) at 'Buy'; Focus Now on June ASCO Presentation

May 9, 2016 11:43 AM EDT

Roth Capital affirms Stemline Therapeutics (Nasdaq: STML) with a Buy rating and $32 price target after the company reported Q1 results on Monday. Stemline posted Q1 EPS of ($0.51), which was $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.

Analyst Joseph Pantginis commented, Following a mostly quiet time in 2015 regarding news flow, which we... More